Onkológia S1/2019
Treatment of patient with metastatic castrate refractory prostate cancer after androgen deprivation therapy failure
Purpose: To describe the effectiveness ARTA (androgen receptor targeted agents) of the metastatic castrate refractory prostate cancer treatment. Case: Patient after androgen deprivation therapy failure was indicated for enzalutamid treatment. Conclusion: The use of ARTA drugs after early detection of progression metastatic prostate cancer to the refractory condition, allows delay biochemical, radiological as well as clinical progression.
Keywords: metastatic castrate refractory prostate cancer, enzalutamid, ARTA, early detection, prostate specific antigen
